Outsourced Pharma White Papers

  1. Transitioning Your Product From Phase 1 To Phase 2 Clinical Studies 12/13/2024

    Strategic partnerships can streamline your transition from Phase 1 to Phase 2 clinical studies, ensuring optimized dosage forms, seamless scale-up, and alignment with patient and study requirements.

  2. Mitigating Nitrosamine Risks In Pharmaceuticals 6/25/2024

    Nitrosamines can come from a range of sources, including raw materials, manufacturing processes, and even water sources. Detecting them requires sensitive analytical methods.

  3. How To Design And Evaluate Bispecific Antibodies (BsAbs)? 11/25/2025

    Bispecific antibodies combine two antigen-binding sites to enhance efficacy and safety. Their design requires structural strategy, MOA-based evaluation, and rigorous screening for optimal therapeutic performance.

  4. Extractables And Leachables Testing 4/9/2024

    Learn how to navigate the extractables and leachables regulatory landscape and implement best practices for leachables analysis in your pharmaceutical development process.

  5. Advancements In Microbial Manufacturing Of Biopharmaceuticals 9/26/2024

    Dive into the evolution and future potential of microbial manufacturing in the biopharmaceutical industry to discover how digital tools can revolutionize development and production processes.

  6. Fill-Finish Contract Manufacturing: Trends, Challenges, And The Future 9/16/2025

    See why it's important to partner with a CDMO that’s investing in advanced sterile fill-finish capabilities to meet the demands of complex biologics, gene therapies, and mRNA-based products.

  7. Preparing For Disease X: Effective Vaccine Development In The Face Of A Future Pandemic 5/8/2024

    CDMOs are playing a critical role in the global effort to prepare for future pandemics. Learn how innovative strategies and flexible platforms are helping to ensure a swift and effective response plan.

  8. Quality By Design (QbD) For Biologics From A CDMO Perspective 2/18/2025

    Adopt QbD principles in your biologics development and manufacturing process to ensure consistent product quality, mitigate risks, and align with patient safety and commercial success goals.

  9. Nose To Brain (N2B) Drug Delivery – Benefits And Challenges 11/20/2024

    Delve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).

  10. The Value Of Engaging A Single CDMO For Comprehensive Biologics Services 2/4/2026

    By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.